ArticleScientific reports2026
Computational identification of Terminalia arjuna phytochemicals as potential 3α-HSD3 inhibitors.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
3α-Hydroxysteroid dehydrogenase type 3 (3α-HSD3) is a key steroid-metabolizing enzyme involved in the regulation of intratumoral androgen and estrogen levels, predominantly in estrogen receptor-positive (ER⁺) MCF-7 breast cancer cells. Its dysregulation influences proliferation, survival, and resistance to hormone-based therapy. The main goal of this study is to identify potential natural inhibitors of 3α-HSD3 from Terminalia arjuna phytoconstituents to modulate MCF-7 breast cancer cell proliferation. A panel of nine phytochemicals were evaluated through molecular docking, ADMET profiling, HOMO-LUMO energy gap analysis, and prediction of activity spectra for substances (PASS) to assess their drug-likeness and preliminary activity. Subsequently, molecular dynamics (MD) simulations were performed on top candidates to explore the structural stability and interaction dynamics of protein-ligand complexes. The selected compounds exhibited favorable docking scores against 3α-HSD3, with Luteolin(CMP1), Leucocyanidin(CMP2), Gallic Acid(CMP3), and Ellagic Acid(CPM4) forming stable hydrogen bonds with key active site residues. This study showed that the top four compounds may serve as potential 3α-HSD3 inhibitors of breast cancer, warranting further in vivo validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.